Bernd Jilma

23.5k total citations · 2 hit papers
562 papers, 16.7k citations indexed

About

Bernd Jilma is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Immunology. According to data from OpenAlex, Bernd Jilma has authored 562 papers receiving a total of 16.7k indexed citations (citations by other indexed papers that have themselves been cited), including 192 papers in Hematology, 163 papers in Cardiology and Cardiovascular Medicine and 117 papers in Immunology. Recurrent topics in Bernd Jilma's work include Platelet Disorders and Treatments (106 papers), Antiplatelet Therapy and Cardiovascular Diseases (104 papers) and Venous Thromboembolism Diagnosis and Management (68 papers). Bernd Jilma is often cited by papers focused on Platelet Disorders and Treatments (106 papers), Antiplatelet Therapy and Cardiovascular Diseases (104 papers) and Venous Thromboembolism Diagnosis and Management (68 papers). Bernd Jilma collaborates with scholars based in Austria, United States and Germany. Bernd Jilma's co-authors include Jolanta M. Siller‐Matula, Alexander Spiel, James C. Gilbert, Oswald Wagner, Christa Firbas, Petra Stohlawetz, Florian Mayr, Michael Schwameis, Ulla Derhaschnig and Petra Jilma‐Stohlawetz and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Bernd Jilma

546 papers receiving 16.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

2016 429 citations Bernd Jilma et al. profile →
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

2019 286 citations Bernd Jilma, Alexander Röth et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bernd Jilma	4.8k	4.4k	2.9k	2.5k	2.4k	562	16.7k
Joost C.M. Meijers	3.3k 0.7×	5.9k 1.3×	2.0k 0.7×	2.3k 0.9×	2.1k 0.9×	354	16.0k
Hugo Ten Cate	5.6k 1.2×	7.7k 1.7×	2.7k 0.9×	3.5k 1.4×	3.3k 1.4×	568	21.5k
Nigel S. Key	3.2k 0.7×	9.6k 2.2×	1.6k 0.6×	1.2k 0.5×	2.3k 1.0×	348	19.3k
Jerrold H. Levy	6.8k 1.4×	3.4k 0.8×	1.1k 0.4×	3.0k 1.2×	6.2k 2.6×	472	23.6k
Oswald Wagner	2.7k 0.5×	1.3k 0.3×	2.3k 0.8×	2.2k 0.9×	2.0k 0.8×	303	14.3k
Marie‐Christine Alessi	5.7k 1.2×	5.1k 1.1×	1.4k 0.5×	4.5k 1.8×	3.3k 1.4×	320	19.0k
Emmanuel J. Favaloro	3.8k 0.8×	7.9k 1.8×	1.1k 0.4×	752 0.3×	3.2k 1.3×	704	15.9k
Thomas L. Ortel	4.9k 1.0×	5.3k 1.2×	1.2k 0.4×	798 0.3×	4.1k 1.7×	277	15.5k
Peter Verhamme	7.1k 1.5×	1.7k 0.4×	726 0.2×	1.8k 0.7×	2.3k 1.0×	350	13.1k
Guy A. Zimmerman	2.9k 0.6×	5.5k 1.2×	8.6k 2.9×	3.7k 1.5×	3.9k 1.6×	262	32.6k

Countries citing papers authored by Bernd Jilma

Since Specialization

Citations

This map shows the geographic impact of Bernd Jilma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Jilma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Jilma more than expected).

Fields of papers citing papers by Bernd Jilma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Jilma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Jilma. The network helps show where Bernd Jilma may publish in the future.

Co-authorship network of co-authors of Bernd Jilma

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Jilma. A scholar is included among the top collaborators of Bernd Jilma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Jilma. Bernd Jilma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gelbenegger, Georg, Bernd Jilma, Jolanta M. Siller‐Matula, et al.. (2024). Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial. Resuscitation. 201. 110273–110273. 6 indexed citations

Thalhammer, Renate, Christian Sillaber, Ulla Derhaschnig, et al.. (2024). Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial. Frontiers in Medicine. 11. 1481333–1481333. 2 indexed citations

Jorda, Anselm, Ivor S. Douglas, Thomas Staudinger, et al.. (2024). Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial. Critical Care. 28(1). 231–231. 5 indexed citations

Grafeneder, Juergen, Gero Langer, Christian Schoergenhofer, et al.. (2024). The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo. Journal of Thrombosis and Thrombolysis. 57(8). 1339–1348. 1 indexed citations

Mühlbacher, Jakob, Farsad Eskandary, Martin Schiemann, et al.. (2024). Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First‐in‐Human Trial Utilizing Sutimlimab. Journal of Medical Virology. 96(11). e70039–e70039. 2 indexed citations

Thanhaeuser, Margarita, Fabian Eibensteiner, Robin Ristl, et al.. (2023). Polyunsaturated Fatty Acid Intake during Complementary Feeding and Neurodevelopmental Outcome in Very Low Birth Weight Infants. Nutrients. 15(14). 3141–3141. 4 indexed citations

Franchi, Francesco, Fabiana Rollini, Luis Ortega‐Paz, et al.. (2023). Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 16(20). 2528–2539. 10 indexed citations

Mayer, Katharina A., Klemens Budde, Philip F. Halloran, et al.. (2022). Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 23(1). 270–270. 15 indexed citations

Thanhaeuser, Margarita, Fabian Eibensteiner, Susanne Brandstetter, et al.. (2022). Preterm Infants on Early Solid Foods and Iron Status in the First Year of Life—A Secondary Outcome Analysis of a Randomized Controlled Trial. Nutrients. 14(13). 2732–2732. 2 indexed citations

10.

Haiden, Nadja, Margarita Thanhaeuser, Fabian Eibensteiner, et al.. (2022). Randomized Controlled Trial of Two Timepoints for Introduction of Standardized Complementary Food in Preterm Infants. Nutrients. 14(3). 697–697. 7 indexed citations

11.

Thanhaeuser, Margarita, Fabian Eibensteiner, Susanne Brandstetter, et al.. (2022). Preterm Infants on Early Solid Foods and Vitamin D Status in the First Year of Life—A Secondary Outcome Analysis of a Randomized Controlled Trial. Nutrients. 14(15). 3105–3105. 2 indexed citations

12.

Ay, Cihan, Ingrid Pabinger, Georg Gelbenegger, et al.. (2022). The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Advances. 6(18). 5467–5476. 20 indexed citations

13.

Klimek, Peter, Martin Brunner, Gerhard Garhöfer, et al.. (2022). Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus. JMIR Medical Informatics. 10(6). e34204–e34204. 5 indexed citations

14.

Mühlbacher, Jakob, Christian Schörgenhofer, Konstantin Doberer, et al.. (2021). Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transplant International. 34(8). 1542–1552. 7 indexed citations

15.

Hofer, Stefanie, Christof Jungbauer, Alexandra Kaider, et al.. (2020). Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. Blood Advances. 4(20). 5157–5164. 32 indexed citations

16.

Nopp, Stephan, Florian Moik, Bernd Jilma, Ingrid Pabinger, & Cihan Ay. (2020). Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis. Research and Practice in Thrombosis and Haemostasis. 4(7). 1178–1191. 286 indexed citations

17.

Puhm, Florian, Taras Afonyushkin, Ulrike Resch, et al.. (2019). Mitochondria Are a Subset of Extracellular Vesicles Released by Activated Monocytes and Induce Type I IFN and TNF Responses in Endothelial Cells. Circulation Research. 125(1). 43–52. 201 indexed citations

18.

Berentsen, Sigbjørn, et al.. (2019). Cold agglutinin disease: current challenges and future prospects. SHILAP Revista de lepidopterología. 1 indexed citations

19.

Eskandary, Farsad, Michael Dürr, Klemens Budde, et al.. (2019). Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 20(1). 37–37. 41 indexed citations

20.

Mayr, Florian, Alexander Spiel, Judith Leitner, et al.. (2004). Effects of Carbon Monoxide Inhalation during Experimental Endotoxemia in Humans. American Journal of Respiratory and Critical Care Medicine. 171(4). 354–360. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact